Literature DB >> 29511594

Imbalance of a KLF4-miR-7 auto-regulatory feedback loop promotes prostate cancer cell growth by impairing microRNA processing.

Lian-Zi Wei1, Yan-Qing Wang2, Yun-Li Chang1, Na An1, Xiao Wang1, Pei-Jie Zhou1, Helen He Zhu1, Yu-Xiang Fang1, Wei-Qiang Gao1,3,4.   

Abstract

The microRNA-transcription factor auto-regulatory feedback loop is a pivotal mechanism for homeostatic regulation of gene expression, and dysregulation of the feedback loop is tightly associated with tumorigenesis and progression. However, the mechanism underlying such dysregulation is still not well-understood. Here we reported that Krüppel-like factor 4 (KLF4), a stemness-associated transcription factor, promotes the transcription of miR-7 to repress its own translation so that a KLF4-miR-7 auto-regulatory feedback loop is established for mutual regulation of their expression. Interestingly, this feedback loop is unbalanced in prostate cancer (PCa) cell lines and patient samples due to an impaired miR-7-processing, leading to decreased mature miR-7 production and attenuated inhibition of KLF4 translation. Mechanistically, enhanced oncogenic Yes associated protein (YAP) nuclear translocation mediates sequestration of p72, a co-factor of the Drosha/DGCR8 complex for pri-miR-7s processing, leading to attenuation of microprocessors' efficiency. Knockdown of YAP or transfection with a mature miR-7 mimic can significantly recover miR-7 expression to restore this feedback loop, and in turn to inhibit cancer cell growth by repressing KLF4 expression in vitro. Thus, our findings indicate that targeting the KLF4-miR-7 feedback loop might be a potential strategy for PCa therapy.

Entities:  

Keywords:  KLF4; YAP; miR-7; microRNA processing; prostate cancer

Year:  2018        PMID: 29511594      PMCID: PMC5835691     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  33 in total

1.  Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer.

Authors:  Masaki Mori; Robinson Triboulet; Morvarid Mohseni; Karin Schlegelmilch; Kriti Shrestha; Fernando D Camargo; Richard I Gregory
Journal:  Cell       Date:  2014-02-27       Impact factor: 41.582

2.  The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs.

Authors:  Ulrich Wellner; Jörg Schubert; Ulrike C Burk; Otto Schmalhofer; Feng Zhu; Annika Sonntag; Bettina Waldvogel; Corinne Vannier; Douglas Darling; Axel zur Hausen; Valerie G Brunton; Jennifer Morton; Owen Sansom; Julia Schüler; Marc P Stemmler; Christoph Herzberger; Ulrich Hopt; Tobias Keck; Simone Brabletz; Thomas Brabletz
Journal:  Nat Cell Biol       Date:  2009-11-22       Impact factor: 28.824

3.  MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions.

Authors:  Sirigiri Divijendra Natha Reddy; Kazufumi Ohshiro; Suresh K Rayala; Rakesh Kumar
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

4.  Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer.

Authors:  Esra Guzel; Omer F Karatas; Mehmet B Duz; Mustafa Solak; Michael Ittmann; Mustafa Ozen
Journal:  Prostate       Date:  2014-08-29       Impact factor: 4.104

5.  Long non-coding RNA UCA1 contributes to the progression of prostate cancer and regulates proliferation through KLF4-KRT6/13 signaling pathway.

Authors:  Xin-Yu Na; Zong-Yuan Liu; Peng-Peng Ren; Rui Yu; Xiao-Song Shang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

6.  Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.

Authors:  Sooryanarayana Varambally; Qi Cao; Ram-Shankar Mani; Sunita Shankar; Xiaosong Wang; Bushra Ateeq; Bharathi Laxman; Xuhong Cao; Xiaojun Jing; Kalpana Ramnarayanan; J Chad Brenner; Jindan Yu; Jung H Kim; Bo Han; Patrick Tan; Chandan Kumar-Sinha; Robert J Lonigro; Nallasivam Palanisamy; Christopher A Maher; Arul M Chinnaiyan
Journal:  Science       Date:  2008-11-13       Impact factor: 47.728

7.  MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia.

Authors:  Huashan Ye; Xiaowen Liu; Meng Lv; Yuliang Wu; Shuzhen Kuang; Jing Gong; Ping Yuan; Zhaodong Zhong; Qiubai Li; Haibo Jia; Jun Sun; Zhichao Chen; An-Yuan Guo
Journal:  Nucleic Acids Res       Date:  2012-02-23       Impact factor: 16.971

8.  Consent for use of clinical leftover biosample: a survey among Chinese patients and the general public.

Authors:  Yi Ma; HuiLi Dai; LiMin Wang; LiJun Zhu; HanBing Zou; XianMing Kong
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

9.  The modulation of Dicer regulates tumor immunogenicity in melanoma.

Authors:  Nicholas C Hoffend; William J Magner; Thomas B Tomasi
Journal:  Oncotarget       Date:  2016-07-26

Review 10.  The long and short of microRNA.

Authors:  Luke A Yates; Chris J Norbury; Robert J C Gilbert
Journal:  Cell       Date:  2013-04-25       Impact factor: 41.582

View more
  4 in total

1.  Downregulation of circular RNA hsa_circ_0000735 boosts prostate cancer sensitivity to docetaxel via sponging miR-7.

Authors:  Yisheng Gao; Jie Liu; Jing Huan; Fengyuan Che
Journal:  Cancer Cell Int       Date:  2020-07-22       Impact factor: 5.722

Review 2.  Recent Discoveries on the Involvement of Krüppel-Like Factor 4 in the Most Common Cancer Types.

Authors:  Agnieszka Taracha-Wisniewska; Grzegorz Kotarba; Sebastian Dworkin; Tomasz Wilanowski
Journal:  Int J Mol Sci       Date:  2020-11-22       Impact factor: 5.923

3.  MiR-135b-5p is an oncogene in pancreatic cancer to regulate GPRC5A expression by targeting transcription factor KLF4.

Authors:  Daren Liu; Yun Jin; Jinhong Wu; Huanbing Zhu; Dan Ye
Journal:  Cell Death Discov       Date:  2022-01-13

4.  miR-152-3p Affects the Progression of Colon Cancer via the KLF4/IFITM3 Axis.

Authors:  Xiaoyi Zhu; Zhan Shen; Da Man; Hang Ruan; Sha Huang
Journal:  Comput Math Methods Med       Date:  2020-09-01       Impact factor: 2.238

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.